Truvada vs Descovy: Tenofovir DF vs AF for HIV PrEP

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Truvada vs Descovy: Tenofovir DF vs AF for HIV PrEP

Quick Answer: Truvada (TDF + FTC) and Descovy (TAF + FTC) are equally effective at preventing HIV — both are FDA-approved for daily oral PrEP and both showed >99% protection in head-to-head trials. The differences are in side-effect profile: TAF (Descovy) is gentler on kidneys and bones; TDF (Truvada) is lipid-neutral and lower-cost as a WHO-GMP generic. Descovy is not yet approved for cis women for vaginal-sex prevention (clinical data still being collected), so Truvada (or its generic Tenvir-EM) remains the default for cis women and people who use injection drugs. This guide unpacks the head-to-head.

What’s in Each Pill

Both regimens contain the same emtricitabine (FTC) — a cytidine nucleoside analogue that blocks reverse transcription. The only difference is the tenofovir prodrug.

The Tenofovir Story: TDF vs TAF

Tenofovir is the workhorse antiretroviral. It can’t be absorbed well as the parent compound, so it’s delivered as a prodrug. TDF (tenofovir disoproxil fumarate) and TAF (tenofovir alafenamide) are two different prodrug strategies for getting the same active molecule (tenofovir diphosphate) into cells.

TDF: The Original Prodrug

TDF was approved in 2001. After absorption, it’s converted to tenofovir in plasma, then taken up by cells and phosphorylated to the active diphosphate form. The plasma half-life means circulating tenofovir levels stay relatively high, and proximal renal tubular cells — which use the OAT1 and OAT3 transporters to take up tenofovir — see significant drug exposure. This is the mechanism behind TDF’s mild renal and bone effects.

TAF: The Refined Prodrug

TAF was approved in 2015. The chemistry is engineered so that the prodrug stays intact in plasma and is cleaved only inside target cells (lymphocytes, hepatocytes). Result: intracellular tenofovir diphosphate concentrations are 4–7× higher than with TDF, while plasma tenofovir levels are 90% lower. Renal and bone exposure to free tenofovir drops to about a tenth of TDF — hence the cleaner kidney and bone profile.

The trade-off is that TAF doesn’t dampen lipid metabolism the way TDF does. TDF was noticed in real-world use to cause a small but consistent decrease in LDL-cholesterol and triglycerides; TAF removes that effect. People on TAF tend to gain 1–3 kg over the first year compared to TDF, with proportionally modest lipid increases.

Head-to-Head: The DISCOVER Trial

DISCOVER was the pivotal randomised non-inferiority trial that got Descovy approved for PrEP. Conducted at 94 sites across the US and Europe, 5,387 cis men who have sex with men and trans women were randomised to Descovy or Truvada and followed for a median of 96 weeks.

Research spotlight — DISCOVER outcomes (Mayer et al, The Lancet 2020):

• HIV infections: 7 on Descovy, 15 on Truvada (incidence 0.16 vs 0.34 per 100 person-years)
• The difference was statistically non-inferior in the per-protocol analysis; Descovy was numerically slightly better, but the trial wasn’t powered to claim superiority
• Renal markers: eGFR dropped 2.5 mL/min/1.73 m² on Truvada vs +1.8 mL/min/1.73 m² on Descovy at week 48
• Bone mineral density: -1.0% to -1.4% loss on Truvada at hip/spine vs +0.5% gain on Descovy
• Lipids: total cholesterol +18 mg/dL on Descovy vs +6 mg/dL on Truvada at week 48
• Weight gain: median +1.5 kg on Descovy vs +0.4 kg on Truvada

Bottom line: both work. The clinically meaningful differences are renal/bone (Descovy wins) and metabolic (Truvada wins).

The Cis Women Gap

DISCOVER enrolled only cis men who have sex with men and trans women. It did not enrol cis women. As a result, the FDA approval for Descovy as PrEP is limited to “individuals at risk through anal sex” — it is not approved for HIV prevention in cis women through vaginal sex.

The reason is biological: TAF achieves high intracellular tenofovir concentrations in lymphocytes, but the vaginal mucosa appears to accumulate tenofovir at lower levels with TAF than with TDF. Whether this translates to actual reduced efficacy in cis women is unknown — no head-to-head trial has been completed in that population.

Current US, UK, and WHO guidance: cis women who want PrEP should use TDF/FTC (Truvada or Tenvir-EM/Tenof-EM/Ricovir-EM), not TAF/FTC. People who inject drugs also use TDF/FTC because that’s the only formulation with trial data in that population (the Bangkok Tenofovir Study).

When to Choose Descovy / Tenvir-AF

• You have pre-existing CKD or eGFR <60 mL/min/1.73 m²
• You’re >50 with hypertension, diabetes, or other renal risk factors
• You have a history of fragility fracture or osteoporosis
• You’re a post-menopausal woman or hypogonadal man
• You’re on long-term NSAIDs or other nephrotoxic drugs
• You’re younger, fit, and want the cleaner long-term renal/bone profile preventively — reasonable but not strictly necessary

When to Choose Truvada / Tenvir-EM

• You’re a cis woman — only TDF/FTC is approved for vaginal-sex prevention
• You inject drugs — only TDF/FTC has trial data in this population
• You have metabolic syndrome, dyslipidaemia, or active weight management concerns
• You have normal renal function and bone density and want the lower-cost option — TDF/FTC generics are widely available at very low prices and are the default for global PrEP scale-up programmes
• You want the longest real-world dataset — TDF/FTC has 13+ years of PrEP data, vs ~5 years for TAF/FTC

Practical Differences for Daily Life

Pill Size and Daily Routine

Truvada-type pills (TDF/FTC) are slightly larger because TDF is dosed at 300 mg. Descovy-type pills (TAF/FTC) are smaller because TAF is dosed at only 25 mg. Both are taken once daily with or without food; food doesn’t materially change absorption.

On-Demand Dosing (2-1-1)

The 2-1-1 on-demand dosing schedule (2 pills 2–24 h before sex, 1 at 24 h after, 1 at 48 h after) is validated for TDF/FTC in MSM only (IPERGAY trial). It is NOT validated for TAF/FTC. If you’re using on-demand PrEP, Truvada / Tenvir-EM is the only correct option.

Switching Between Them

You can switch directly without a washout — start the new pill the day after the last dose of the old one. Repeat baseline tests (HIV, creatinine) at the next standard visit.

Cost and Access

This is where the practical math diverges sharply.

• Branded Truvada in the US has been listed at $1,900–$2,200/month wholesale historically; now sells generically at around $30–$60/month at US chain pharmacies via discount programs
• WHO-GMP TDF/FTC generics (Tenvir-EM, Tenof-EM, Ricovir-EM) — typically <$20/month delivered via international order
• Branded Descovy in the US — still around $1,700–$2,000/month wholesale; less generic competition because patent expiry is staggered
• WHO-GMP TAF/FTC generic Tenvir-AF — typically $25–$40/month delivered

The global health economics is clear: WHO-GMP-certified generics from Cipla, Hetero, and Mylan are the engine of worldwide PrEP scale-up. Both TDF/FTC and TAF/FTC generics are bioequivalent to the originator products under WHO prequalification.

What the Data Doesn’t Tell Us Yet

• Long-term TAF effects in young users. TAF has 5+ years of real-world data; TDF has 13+. The TAF safety profile looks excellent so far, but very long-term effects (10+ years) are still being characterised.
• TAF efficacy in vaginal-sex PrEP for cis women. Ongoing trials should produce data by 2026–2027.
• TAF-related weight gain mechanisms. Whether this is direct metabolic effect or a “return to health” effect (TDF was mildly suppressing weight) is contested.

Frequently Asked Questions

Which is more effective at preventing HIV?

Both are >99% effective with consistent adherence. DISCOVER found numerical superiority for Descovy but the trial was designed to test non-inferiority. In real-world terms, the choice depends on side-effect profile, not efficacy.

Can I take Descovy if I’m a cis woman?

It’s not yet FDA-approved for that indication, and current global guidance recommends TDF/FTC (Truvada / Tenvir-EM) for cis women using PrEP for vaginal sex prevention. Wait for the cis-women trial data before switching to TAF/FTC.

Are generics like Tenvir-EM and Tenvir-AF as good as Truvada and Descovy?

Yes. Cipla, Hetero, and Mylan generics are bioequivalent to the originator products under WHO prequalification. The 2024 Lancet HIV review of generic PrEP performance confirmed identical efficacy outcomes in real-world cohorts.

What if I have a kidney problem and metabolic syndrome?

You’re stuck choosing the smaller of two trade-offs. Most clinicians prioritise kidney protection (TAF/Descovy/Tenvir-AF) and manage lipids/weight separately with diet and statin therapy as needed.

Can I switch back to Truvada if I gain weight on Descovy?

Yes. Switching back is straightforward — just start TDF/FTC the day after your last TAF/FTC dose. Weight typically stabilises or trends down over 3–6 months.

What about Apretude (cabotegravir injection)?

Long-acting injectable PrEP exists (cabotegravir IM every 2 months) but is not an oral pill. It’s an alternative pathway entirely, not a Descovy alternative. Current barriers are cost and access. Daily oral PrEP remains the global mainstay.

Medical Disclaimer: Choice between TDF/FTC and TAF/FTC depends on individual renal function, bone health, metabolic profile, and sex/exposure type. Both regimens require baseline and ongoing HIV testing, kidney monitoring, and STI screening. Always work with a qualified healthcare provider for selection, monitoring, and switching decisions.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.